Original language | English |
---|---|
Pages (from-to) | 375-382 |
Number of pages | 8 |
Journal | Hypertension |
Volume | 71 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2018 |
Bibliographical note
Funding Information:J.-G. Wang received lecture and consulting fees from Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda. K. Kario received research funding from Teijin Pharma Limited, Omron Healthcare Co., Ltd., Fukuda Denshi, Bayer Yakuhin Ltd., A &D Co., Ltd., Daiichi Sankyo Company, Limited, Mochida Pharmaceutical Co., Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi & Co., Ltd., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Company Limited and Omron Healthcare Co., Ltd. The other authors report no conflicts.
Funding Information:
The meetings held between the authors to discuss and prepare this manuscript were funded by an unrestricted educational grant from Daiichi Sankyo Co. Ltd.
Funding Information:
We acknowledge Dr Cathy Chow (Calico Communications) for editorial support, which was funded by Daiichi Sankyo Co. Ltd, and Haruo Anzai (Daiichi Sankyo Co. Ltd.) and Mitsunori Sugiyama (Daiichi Sankyo Co. Ltd.) for their logistical support.
ASJC Scopus subject areas
- Internal Medicine